Treatment of patients with pineoblastoma with high dose cyclophosphamide.

Journal Article (Journal Article)

The outcome for patients with pineoblastoma has historically been very poor, with most patients dying of disseminated disease despite irradiation. Furthermore, the low incidence of this tumor has hindered progress toward defining better treatment strategies. Here we report the activity and toxicity of cyclophosphamide administered as a single agent at a dose schedule of 2 g/m2/day for 2 successive days at monthly intervals for a maximum of four courses. Eight patients were evaluated, six newly diagnosed and two recurrent. Amongst the six newly diagnosed patients, there were three patients demonstrating partial responses, and three had stable disease throughout the cyclophosphamide treatment period. All six patients are alive and disease free after further therapy. One patient with recurrent disease demonstrated tumor progression on cyclophosphamide, and the other had stable disease throughout the cyclophosphamide treatment period. Both patients subsequently died of progressive disease. The major toxicity of high dose cyclophosphamide was hematopoietic, with one patient requiring a dose reduction after three courses due to prolonged thrombocytopenia. One patient was also withdrawn from treatment with cyclophosphamide due to impaired pulmonary function. This study demonstrates the activity of high dose cyclophosphamide in the treatment of pineoblastoma and may serve as basis for the design of future studies of this tumor.

Full Text

Duke Authors

Cited Authors

  • Ashley, DM; Longee, D; Tien, R; Fuchs, H; Graham, ML; Kurtzberg, J; Casey, J; Olson, J; Meier, L; Ferrell, L; Kerby, T; Duncan-Brown, M; Stewart, E; Colvin, OM; Pipas, JM; McCowage, G; McLendon, R; Bigner, DD; Friedman, HS

Published Date

  • June 1996

Published In

Volume / Issue

  • 26 / 6

Start / End Page

  • 387 - 392

PubMed ID

  • 8614374

International Standard Serial Number (ISSN)

  • 0098-1532

Digital Object Identifier (DOI)

  • 10.1002/(SICI)1096-911X(199606)26:6<387::AID-MPO3>3.0.CO;2-D


  • eng

Conference Location

  • United States